Based on the latest 2018Q3 regulatory filing with the SEC, Northern Cross Llc decreased its holdings in Teva Pharmaceutical (TEVA) by 96.18%. The company’s stock sank 12.44% while Northern Cross Llc sold 21.64M shares. At the end of 2018Q3, the institutional investor held 860,538 shares of the major pharmaceuticals company, valued at $18.54M, down from 22.50M at the end of the previous reported quarter. For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is anticipated to reveal earnings on February, 14., Zacks reports. EPS of $0.53 is 41.76 % down from 2018’s $0.91 EPS. TEVA’s profit could be $577.51M if the current EPS of $0.53 is accurate. Analysts at Wall Street see Teva Pharmaceutical Industries Limited’s -17.19 % negative EPS growth compared to $0.64 EPS for last quarter.

For more Teva Pharmaceutical Industries Limited (NYSE:TEVA) news released recently go to: Seekingalpha.com, 247Wallst.com, Seekingalpha.com, Fool.com or Fool.com. The titles are as follows: “Teva – Reasonable Start To 2018 Alleviates Immediate Concerns – Seeking Alpha” released on May 31, 2018, “Top Analyst Upgrades and Downgrades: Alphabet, Amazon, Dell, IBM, International Paper, Merck, Pfizer, Tesla, Teva, Walmart and More – 24/7 Wall St.” on January 23, 2019, “Teva Pharmaceuticals: 37% Improvement In Net Income Year Over Year – Seeking Alpha” with a publish date: December 25, 2018, “Teva Pharmaceutical Stock Wins 2 Upgrades: What You Need to Know – The Motley Fool” and the last “Why Teva Pharmaceutical Industries, Tivity Health, and Marine Products Slumped Today – The Motley Fool” with publication date: December 10, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

In total 8 analysts cover Teva Pharmaceutical Indus (NYSE:TEVA). “Buy” rating has 4, “Sell” are 0, while 4 are “Hold”. 50% are bullish. 10 are the (NYSE:TEVA)’s analyst reports since September 7, 2018 according to StockzIntelligence Inc. The stock rating was maintained by Credit Suisse with “Neutral” on Monday, September 17. In Thursday, January 3 report Bank of America upgraded the stock to “Buy” rating. On Monday, November 5 the firm has “Overweight” rating by Morgan Stanley given. On Friday, September 7 the stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Neutral” rating given by Credit Suisse. On Monday, September 17 the stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Buy” rating given by Mizuho. On Monday, October 1 the stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Buy” rating given by Goldman Sachs. On Wednesday, January 23 the firm earned “Neutral” rating by PiperJaffray. On Monday, September 17 BTIG Research upgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) to “Neutral” rating. On Friday, November 2 the rating was maintained by Bank of America with “Underperform”. In Monday, October 1 report Leerink Swann upgraded the stock to “Market Perform” rating.